Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT00148798 Completed - Clinical trials for Non Small Cell Lung Cancer (NSCLC)

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)

FLEX
Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.

NCT ID: NCT00148395 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.

Start date: June 2002
Phase: Phase 3
Study type: Interventional

This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer. It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different strategies of sequential single-agent, sequential double-agent or sequential triple-agent therapy.

NCT ID: NCT00148291 Completed - Lung Cancer Clinical Trials

Phase III Study of Docetaxel Vs Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer

Start date: June 1999
Phase: Phase 3
Study type: Interventional

Vinorelbine is currently the standard treatment for elderly patients with advanced non-small cell lung cancer (NSCLC). Docetaxel has also shown promising results against elderly patients in phase II studies. We conducted a randomized phase III trial to evaluate whether docetaxel provided better overall survival than vinorelbine in elderly patients with advanced NSCLC.

NCT ID: NCT00144989 Completed - Clinical trials for Small-Cell-Lung Cancer

A Study Comparing Irinotecan and Cisplatin (IP) With Etoposide and Cisplatin (EP) Following EP/TRT for LD-SCLC

Start date: September 2002
Phase: Phase 3
Study type: Interventional

To evaluate the role of 3 cycles of irinotecan and cisplatin for patients with limited-stage small-cell lung cancer who received one course of etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic irradiation.

NCT ID: NCT00144066 Completed - Lung Cancer Clinical Trials

A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer

Start date: January 2003
Phase: Phase 3
Study type: Interventional

A randomized phase III trial of platinum-based chemotherapy alone versus platinum-based chemotherapy followed by maintenance therapy with gefitinib in patients with stage IIIB/IV NSCLC.

NCT ID: NCT00144053 Completed - Lung Cancer Clinical Trials

A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

Start date: April 2001
Phase: Phase 3
Study type: Interventional

To evaluate whether two weekly concurrent chemoradiotherapy regimens offer any advantage over concurrent chemoradiotherapy regimens with Cisplatin, Vindesine, Mitomycin for unresectable stage III NSCLC.

NCT ID: NCT00143455 Completed - Clinical trials for Small Cell Lung Carcinoma

Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer

Start date: June 2002
Phase: Phase 3
Study type: Interventional

To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung Cancer (ED-SCLC).

NCT ID: NCT00138658 Completed - Clinical trials for Non-small Cell Lung Cancer

A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Start date: November 2004
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study will help determine if giving OGX-011 (custirsen sodium) in combination with gemcitabine (GEM) and cisplatin (CIS) or carboplatin (CARB) is a safe and effective treatment for patients with lung cancer. This study will help to assess the safety and anti-tumor effect of OGX-011 when given to patients in combination with GEM and CIS/CARB.

NCT ID: NCT00138203 Completed - Clinical trials for Stage IV Non-small Cell Lung Cancer

Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Start date: June 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with stage IIIB, stage IV, or recurrent non-small cell lung cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00137800 Completed - Clinical trials for Non-Small-Cell Lung Carcinoma

Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients

Start date: February 2003
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to determine whether the drug OSI-774 is less toxic and potentially as good as or better than standard chemotherapy drugs, when given to subjects with non-small cell lung cancer, who are 70 years of age or older.